How to buy Avonib at the cheapest price

Ivosidenib (Ivosidenib), as an innovative drug targeting IDH1 mutations, has received widespread attention in the international cancer treatment field. However, due to the high cost of drug development and long patent protection period, the selling price has always been high. How to obtain treatment at a lower cost is the most concerned issue for many (acute myeloid leukemia, cholangiocarcinoma, myelodysplastic syndrome) patients. The original version is currently on the market in China, but it has not yet been included in medical insurance, so the cost of the drug is entirely borne by the patients themselves. The common specification for a single box is 0.25g × 60 tablets, and the market price reaches tens of thousands of yuan, which is not a small burden for long-term treatment patients.

In contrast, overseas price fluctuations are more obvious. For example, due to the different medical and drug pricing systems of the US version of the original drug, the price of a single box is generally higher, and can even reach a higher range, and will continue to fluctuate due to the impact of exchange rates. Because of this, many patients will pay attention to whether generic drugs have emerged overseas as a cost-controllable alternative. Judging from overseas public information, generic drugs of ivonib have been launched in some countries. For example, some manufacturers in Asia have put the 250mg × 60 tablets on the market. The ingredients of these generic drugs are consistent with the original ones and are produced strictly in accordance with common standards. However, due to lower production costs, their prices are generally more affordable.

To obtain ivonib at a cheaper price, patients can consider several aspects. First, formal cross-border pharmacies or overseas medical channels purchase generic drugs through legal and compliant methods, and the price is usually only a fraction of the original drug. The second is to focus on domestic scientific research projects or patient assistance programs. Some hospitals will conduct real-world research on specific diseases to reduce some costs for eligible patients. However, such opportunities require vetting criteria, and spaces are limited, so not all patients can participate.

In addition, patients should be reminded to avoid purchasing from informal channels "Low-priced original drugs" or unregistered sources. Targeted drugs have extremely high quality requirements, and drugs from unknown sources may not only be ineffective, but may even pose safety risks.

Reference: https://www.tibsovo.com/